217 related articles for article (PubMed ID: 21718937)
1. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A
Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937
[TBL] [Abstract][Full Text] [Related]
2. Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.
Ogawa K; Ishizaki A; Takai K; Kitamura Y; Kiwada T; Shiba K; Odani A
PLoS One; 2013; 8(12):e84335. PubMed ID: 24391942
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
[TBL] [Abstract][Full Text] [Related]
4. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
[TBL] [Abstract][Full Text] [Related]
5. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.
Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O
Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and evaluation of
Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
[TBL] [Abstract][Full Text] [Related]
7. Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously.
Ogawa K; Yu J; Ishizaki A; Yokokawa M; Kitamura M; Kitamura Y; Shiba K; Odani A
Bioconjug Chem; 2015 Aug; 26(8):1561-70. PubMed ID: 26087328
[TBL] [Abstract][Full Text] [Related]
8. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.
Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F
Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354
[TBL] [Abstract][Full Text] [Related]
9. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation.
Ogawa K; Mukai T; Arano Y; Otaka A; Ueda M; Uehara T; Magata Y; Hashimoto K; Saji H
Nucl Med Biol; 2006 May; 33(4):513-20. PubMed ID: 16720243
[TBL] [Abstract][Full Text] [Related]
10. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals.
Ferreira CL; Lamsa E; Woods M; Duan Y; Fernando P; Bensimon C; Kordos M; Guenther K; Jurek P; Kiefer GE
Bioconjug Chem; 2010 Mar; 21(3):531-6. PubMed ID: 20175523
[TBL] [Abstract][Full Text] [Related]
12. New (68)Ga-PhenA bisphosphonates as potential bone imaging agents.
Wu Z; Zha Z; Choi SR; Plössl K; Zhu L; Kung HF
Nucl Med Biol; 2016 Jun; 43(6):360-71. PubMed ID: 27260777
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
14. 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
Koumarianou E; Loktionova NS; Fellner M; Roesch F; Thews O; Pawlak D; Archimandritis SC; Mikolajczak R
Appl Radiat Isot; 2012 Dec; 70(12):2669-76. PubMed ID: 23037921
[TBL] [Abstract][Full Text] [Related]
15. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis.
Prinsen K; Cona MM; Cleynhens BJ; Li J; Vanbilloen H; Dyubankova N; Lescrinier E; Ni Y; Bormans GM; Verbruggen AM
Nucl Med Biol; 2013 Aug; 40(6):816-22. PubMed ID: 23915800
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.
Sano K; Okada M; Hisada H; Shimokawa K; Saji H; Maeda M; Mukai T
Biol Pharm Bull; 2013; 36(4):602-8. PubMed ID: 23546294
[TBL] [Abstract][Full Text] [Related]
18. Development of
Lee JY; Lee SY; Kim GG; Hur MG; Yang SD; Park JH; Kim SW
Cancer Biother Radiopharm; 2017 Jun; 32(5):169-175. PubMed ID: 28598691
[No Abstract] [Full Text] [Related]
19. TE1PA as Innovating Chelator for
Navarro AS; Le Bihan T; Le Saëc P; Bris NL; Bailly C; Saï-Maurel C; Bourgeois M; Chérel M; Tripier R; Faivre-Chauvet A
Bioconjug Chem; 2019 Sep; 30(9):2393-2403. PubMed ID: 31386357
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of a novel 68Ga-labeled DOTA-benzamide derivative for malignant melanoma imaging.
Kim HJ; Kim DY; Park JH; Yang SD; Hur MG; Min JJ; Yu KH
Bioorg Med Chem Lett; 2012 Aug; 22(16):5288-92. PubMed ID: 22796183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
